For the year ending 2025-12-31, BIAF has $10,960,772 in assets. $3,683,116 in debts. $6,449,782 in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 6,449,782 | |||
| Accounts and other receivables, net | 541,962 | |||
| Inventory | 53,548 | |||
| Prepaid expenses and other current assets | 519,916 | |||
| Total current assets | 7,565,208 | |||
| Property and equipment, gross | 969,839 | |||
| Less accumulated depreciation and amortization | 704,246 | |||
| Property and equipment, net | 265,593 | |||
| Operating lease right-of-use asset, net | 334,289 | |||
| Finance lease right-of-use asset, net | 661,575 | |||
| Goodwill | 1,404,486 | |||
| Intangible assets, net | 716,806 | |||
| Other assets | 12,815 | |||
| Total assets | 10,960,772 | |||
| Accounts payable | 761,901 | |||
| Accrued expenses | 1,717,989 | |||
| Unearned revenue | 42,405 | |||
| Operating lease liability, current portion | 139,220 | |||
| Finance lease liability, current portion | 139,490 | |||
| Notes payable, current portion | 105,161 | |||
| Total current liabilities | 2,906,166 | |||
| Operating lease liability, net of current portion | 202,878 | |||
| Finance lease liability, net of current portion | 532,759 | |||
| Notes payable, net of current portion | 41,313 | |||
| Total liabilities | 3,683,116 | |||
| Preferred stock, 0.001 per share 20,000,000 shares authorized 700 and 0 shares issued and outstanding at december 31, 2025 and 2024, respectively | 1 | |||
| Common stock, par value 0.007 per share 350,000,000 shares authorized 4,498,675 and 519,158 issued and outstanding at december 31, 2025 and 2024, respectively() | 31,461 | |||
| Additional paid-in capital | 75,800,258 | |||
| Accumulated deficit | -68,554,064 | |||
| Total stockholders equity | 7,277,656 | |||
| Total liabilities and stockholders equity | 10,960,772 | |||
bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc. (BIAF)